Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.960
Buy
RSI(14)
71.121
Buy
STOCH(KDJ)(9,3,3)
79.792
Neutral
ATR(14)
1.050
High Vlolatility
CCI(14)
75.953
Neutral
Williams %R
17.593
Overbought
TRIX(12,20)
1.094
Sell
StochRSI(14)
24.469
Neutral
Search
Progyny Inc
PGNYAdd to Watchlist
23.250USD
+0.380+1.66%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.82BMarket Cap
28.83P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Progyny Inc
Currency: USD Updated: 2026-05-15Key Insights
Progyny Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 74 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.18.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Progyny Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Progyny Inc Highlights
StrengthsRisks
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 18.38% year-on-year.
Undervalued
The company’s latest PE is 28.83, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.51M shares, decreasing 26.54% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.52K shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
28.182
Target Price
+23.23%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Progyny Inc is 8.30, ranking 15 out of 74 in the Healthcare Providers & Services industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 328.50M, representing a year-over-year increase of 1.38%, while its net profit experienced a year-over-year increase of 60.91%.
Score
Financials
9.17
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
7.92
Growth Potential
7.08
Shareholder Returns
7.33
Progyny Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Progyny Inc is 6.79, ranking 41 out of 74 in the Healthcare Providers & Services industry. Its current P/E ratio is 28.83, which is 302.76% below the recent high of 116.10 and 23.26% above the recent low of 22.12.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 6/74
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Progyny Inc is 8.36, ranking 16 out of 74 in the Healthcare Providers & Services industry. The average price target is 29.50, with a high of 33.00 and a low of 26.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
28.182
Target Price
+23.23%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
9
Total
22
Median
20
Average
Company name
Ratings
Analysts
Progyny Inc
PGNY
11
Unitedhealth Group Inc
UNH
30
Humana Inc
HUM
29
Cigna Group
CI
25
Elevance Health Inc
ELV
25
Centene Corp
CNC
22
1
2
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Progyny Inc is 9.28, ranking 17 out of 74 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 25.97 and the support level at 18.95, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
23.126
Buy
MA10
21.510
Buy
MA20
19.899
Buy
MA50
18.444
Buy
MA100
20.915
Buy
MA200
21.781
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Progyny Inc is 10.00, ranking 1 out of 74 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 113.05%, representing a quarter-over-quarter increase of 8.18%. The largest institutional shareholder is Baillie Gifford, holding a total of 1.22M shares, representing 1.56% of shares outstanding, with 4.67% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Progyny Inc is 6.01, ranking 33 out of 74 in the Healthcare Providers & Services industry. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.98
VaR
+4.81%
240-Day Maximum Drawdown
+42.65%
240-Day Volatility
+54.54%
Return
Best Daily Return
60 days
+23.80%
120 days
+23.80%
5 years
+38.23%
Worst Daily Return
60 days
-20.49%
120 days
-20.49%
5 years
-32.65%
Sharpe Ratio
60 days
+1.12
120 days
-0.02
5 years
-0.04
Risk Assessment
Maximum Drawdown
240 days
+42.65%
3 years
+68.14%
5 years
+79.49%
Return-to-Drawdown Ratio
240 days
+0.17
3 years
-0.19
5 years
-0.15
Skewness
240 days
+1.66
3 years
-1.19
5 years
+0.54
Volatility
Realised Volatility
240 days
+54.54%
5 years
+57.57%
Standardised True Range
240 days
+3.87%
5 years
+6.12%
Downside Risk-Adjusted Return
120 days
-2.14%
240 days
-2.14%
Maximum Daily Upside Volatility
60 days
+54.97%
Maximum Daily Downside Volatility
60 days
+57.20%
Liquidity
Average Turnover Rate
60 days
+1.85%
120 days
+1.75%
5 years
--
Turnover Deviation
20 days
+3.74%
60 days
+2.60%
120 days
-2.99%
Peer Comparison
Healthcare Providers & Services
Progyny Inc
PGNY
8.22 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Encompass Health Corp
EHC
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Concentra Group Holdings Parent Inc
CON
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Pennant Group Inc
PNTG
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Brightspring Health Services Inc
BTSG
8.34 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Hinge Health Inc
HNGE
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
